Unbalanced alternative splicing and its significance in cancer

Alternative pre‐mRNA splicing leads to distinct products of gene expression in development and disease. Antagonistic splice variants of genes involved in differentiation, apoptosis, invasion and metastasis often exist in a delicate equilibrium that is found to be perturbed in tumours. In several recent examples, splice variants that are overexpressed in cancer are expressed as hyper‐oncogenic proteins, which often correlate with poor prognosis, thus suggesting improved diagnosis and follow up treatment. Global gene expression technologies are just beginning to decipher the interplay between alternatively spliced isoforms and protein‐splicing factors that will lead to identification of the mutations in these trans‐acting factors responsible for pathogenic alternative splicing in cancer. BioEssays 28: 378–386, 2006. © 2006 Wiley Periodicals, Inc.

[1]  J. Bruner,et al.  Alternative splicing of neurofibromatosis type 1 gene transcript in malignant brain tumors: PCR analysis of frozen‐section mRNA , 1992, Molecular carcinogenesis.

[2]  M. Dowsett,et al.  Identification of an exon 3 deletion splice variant androgen receptor mRNA in human breast cancer , 1997, International journal of cancer.

[3]  Russ P Carstens,et al.  Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer , 1997, Oncogene.

[4]  P. Jordan,et al.  Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors , 1999, Oncogene.

[5]  N. Heerema,et al.  Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Quinn,et al.  A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker. , 2000, Cancer research.

[7]  H. Hellmich,et al.  Human Colorectal Cancers Express a Constitutively Active Cholecystokinin-B/Gastrin Receptor That Stimulates Cell Growth* , 2000, The Journal of Biological Chemistry.

[8]  J. G. Park,et al.  Novel transcripts of fibroblast growth factor receptor 3 reveal aberrant splicing and activation of cryptic splice sequences in colorectal cancer. , 2000, Cancer research.

[9]  Y. Maehara,et al.  A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhous gastric carcinoma , 2001, Oncogene.

[10]  S. Baker,et al.  EWS/FLI Alters 5′-Splice Site Selection* , 2001, The Journal of Biological Chemistry.

[11]  H. Chansky,et al.  Oncogenic TLS/ERG and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein. , 2001, Cancer research.

[12]  F. Uckun,et al.  Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia , 2001, Oncogene.

[13]  A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. , 2002, The Journal of clinical endocrinology and metabolism.

[14]  T. Imamura,et al.  Expression of the Ikaros gene family in childhood acute lymphoblastic leukaemia , 2002, British journal of haematology.

[15]  H. Grabsch,et al.  Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression , 2002, British Journal of Cancer.

[16]  VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. , 2002, Cancer research.

[17]  Remco Dijkman,et al.  A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. , 2002, Cancer research.

[18]  J. Venables.  Alternative splicing in the testes. , 2002, Current opinion in genetics & development.

[19]  L. Mir,et al.  Bleomycin resistance in mammalian cells expressing a genetic suppressor element derived from the SRPK1 gene. , 2002, Cancer research.

[20]  M. Schrappe,et al.  Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia , 2003, Nature.

[21]  John G. Collard,et al.  Tumor-related Alternatively Spliced Rac1b Is Not Regulated by Rho-GDP Dissociation Inhibitors and Exhibits Selective Downstream Signaling* , 2003, Journal of Biological Chemistry.

[22]  Kenneth M. Yamada,et al.  CrkI adapter protein modulates cell migration and invasion in glioblastoma. , 2003, Cancer research.

[23]  I. Okamoto,et al.  Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors. , 2003, Cancer research.

[24]  W. Symmans,et al.  Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. , 2003, Cancer research.

[25]  Johanne Toutant,et al.  Small interfering RNA-mediated reduction in heterogeneous nuclear ribonucleoparticule A1/A2 proteins induces apoptosis in human cancer cells but not in normal mortal cell lines. , 2003, Cancer research.

[26]  S. Burchill,et al.  FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells , 2003, British Journal of Cancer.

[27]  J. Coon,et al.  Alternative Splicing of the Multidrug Resistance Protein 1/ATP Binding Cassette Transporter Subfamily Gene in Ovarian Cancer Creates Functional Splice Variants and Is Associated with Increased Expression of the Splicing Factors PTB and SRp20 , 2004, Clinical Cancer Research.

[28]  D. Gillatt,et al.  Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein. , 2004, American journal of physiology. Renal physiology.

[29]  S. Edwards,et al.  Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications , 2004, Cellular and Molecular Life Sciences CMLS.

[30]  Hong-cheng Wang,et al.  Multiple variants and a differential splicing pattern of kinectin in human hepatocellular carcinoma. , 2004, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[31]  Marina Ziche,et al.  VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant , 2004, Cancer Research.

[32]  G. Bauerschmitz,et al.  In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells , 2004, Cancer Immunology, Immunotherapy.

[33]  S. Howng,et al.  Differential expression and splicing isoform analysis of human Tcf-4 transcription factor in brain tumors. , 2004, International journal of oncology.

[34]  E. Lengyel,et al.  Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation , 2004, Oncogene.

[35]  W. Jin,et al.  Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements. , 2004, Human molecular genetics.

[36]  C. Townsend,et al.  Agonist-independent Activation of Src Tyrosine Kinase by a Cholecystokinin-2 (CCK2) Receptor Splice Variant* , 2004, Journal of Biological Chemistry.

[37]  H. Findley,et al.  An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy , 2004, Oncogene.

[38]  Deregulation of p73 isoform equilibrium in benign prostate hyperplasia and prostate cancer. , 2004, Oncology reports.

[39]  G. Riggins,et al.  Splicing factors are differentially expressed in tumors. , 2004, Genetics and molecular research : GMR.

[40]  S. Salesse,et al.  p210BCR/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells , 2004, Leukemia.

[41]  L. Dwyer-Nield,et al.  Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: Implications for pre‐mRNA processing , 2004, Molecular carcinogenesis.

[42]  Orianne Théoleyre,et al.  Des oncogènes à l’interface entre transcription et épissage , 2004 .

[43]  F. Zhan,et al.  RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. , 2004, Blood.

[44]  P. Davis,et al.  Molecular mechanisms regulating the tumor-targeting potential of splice-activated gene expression , 2004, Cancer Gene Therapy.

[45]  L. Corcos,et al.  Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. , 2004, Molecular cancer research : MCR.

[46]  I. Screpanti,et al.  TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. , 2004, Cancer cell.

[47]  E. Wiemer,et al.  Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1. , 2004, Neoplasia.

[48]  M. Stearns,et al.  Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4tΔ773–1081 overexpression is diagnostic for sentinel lymph node metastasis , 2004, Laboratory Investigation.

[49]  C. Papadimitriou,et al.  Relative expression of human telomerase catalytic subunit (hTERT) transcripts in astrocytic gliomas , 2004, Acta Neuropathologica.

[50]  J. Kawai,et al.  Libraries enriched for alternatively spliced exons reveal splicing patterns in melanocytes and melanomas , 2004, Nature Methods.

[51]  J. Venables.  Aberrant and Alternative Splicing in Cancer , 2004, Cancer Research.

[52]  R. Siebert,et al.  The BCR-ABL1 Kinase Bypasses Selection for the Expression of a Pre–B Cell Receptor in Pre–B Acute Lymphoblastic Leukemia Cells , 2004, The Journal of Experimental Medicine.

[53]  J. Scheuermann,et al.  Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis. , 2004, Current pharmaceutical design.

[54]  S. Canevari,et al.  A novel isoform of pro-interleukin-18 expressed in ovarian tumors is resistant to caspase-1 and -4 processing , 2004, Oncogene.

[55]  C. Brambilla,et al.  Oligomer-mediated modulation of hTERT alternative splicing induces telomerase inhibition and cell growth decline in human prostate cancer cells , 2004, Cellular and Molecular Life Sciences CMLS.

[56]  D. Galiana-Arnoux,et al.  Intronic UGG repeats coordinate splicing of CD44 alternative exons v8 and v9. , 2005, Biochemical and biophysical research communications.

[57]  Mian Wu,et al.  RIP3 β and RIP3 γ, two novel splice variants of receptor-interacting protein 3 (RIP3), downregulate RIP3-induced apoptosis , 2005 .

[58]  A. Camargo,et al.  Identification of human exons overexpressed in tumors through the use of genome and expressed sequence data. , 2005, Physiological genomics.

[59]  A. Saito,et al.  Candidates for tumor-specific alternative splicing. , 2005, Biochemical and biophysical research communications.

[60]  K. Silina,et al.  Alterations of pre‐mRNA splicing in cancer , 2005, Genes, chromosomes & cancer.

[61]  Michael R Green,et al.  Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. , 2005, Molecular cell.

[62]  S. Hirohashi,et al.  β-Catenin Interacts With the FUS Proto-oncogene Product and Regulates Pre-mRNA Splicing , 2005 .

[63]  J. Rowley,et al.  Mimicry of a constitutively active pre–B cell receptor in acute lymphoblastic leukemia cells , 2005, The Journal of experimental medicine.

[64]  A. Kolokoltsov,et al.  Src Regulates Constitutive Internalization and Rapid Resensitization of a Cholecystokinin 2 Receptor Splice Variant* , 2005, Journal of Biological Chemistry.

[65]  A. Mills.  p53: link to the past, bridge to the future. , 2005, Genes & development.

[66]  J. Manley,et al.  Inactivation of the SR Protein Splicing Factor ASF/SF2 Results in Genomic Instability , 2005, Cell.

[67]  E. McDermott,et al.  Expression of survivin and its splice variants survivin-2B and survivin-ΔEx3 in breast cancer , 2004, British Journal of Cancer.

[68]  B. Joseph,et al.  Full-length p73α Represses Drug-induced Apoptosis in Small Cell Lung Carcinoma Cells* , 2005, Journal of Biological Chemistry.

[69]  Lloyd J. Old,et al.  Cancer/testis antigens, gametogenesis and cancer , 2005, Nature Reviews Cancer.

[70]  H. Kaneto,et al.  Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients. , 2005, Biochemical and biophysical research communications.

[71]  P. Fehlbaum,et al.  A microarray configuration to quantify expression levels and relative abundance of splice variants , 2005, Nucleic acids research.

[72]  M. Garcia-Blanco.  Making antisense of splicing. , 2005, Current opinion in molecular therapeutics.

[73]  Wei Zhang,et al.  Inactivation of the invasion inhibitory gene IIp45 by alternative splicing in gliomas. , 2005, Cancer research.

[74]  F. Li,et al.  Role of survivin and its splice variants in tumorigenesis , 2004, British Journal of Cancer.

[75]  S. Miyatake,et al.  Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas. , 2005, Oncology reports.

[76]  John C. Castle,et al.  Evolutionarily conserved and diverged alternative splicing events show different expression and functional profiles , 2005, Nucleic acids research.

[77]  F. Clark,et al.  Understanding alternative splicing: towards a cellular code , 2005, Nature Reviews Molecular Cell Biology.

[78]  D. Schaid,et al.  A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. , 2005, Cancer research.

[79]  S. Harper,et al.  Therapeutic potential of inhibitory VEGF splice variants. , 2005, Future oncology.

[80]  H. Harris.  A long view of fashions in cancer research. , 2005, BioEssays : news and reviews in molecular, cellular and developmental biology.

[81]  Christopher J. Lee,et al.  Evidence that public database records for many cancer-associated genes reflect a splice form found in tumors and lack normal splice forms , 2005, Nucleic acids research.

[82]  G. Henze,et al.  Expression of interleukin-10 splicing variants is a positive prognostic feature in relapsed childhood acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  K. Döhner,et al.  Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis , 2005, Oncogene.

[84]  S. Friedman,et al.  Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. , 2005, Cancer research.

[85]  V. Beneš,et al.  Alternative Splicing Microarrays Reveal Functional Expression of Neuron-specific Regulators in Hodgkin Lymphoma Cells* , 2005, Journal of Biological Chemistry.

[86]  J. Manley,et al.  Loss of splicing factor ASF/SF2 induces G2 cell cycle arrest and apoptosis, but inhibits internucleosomal DNA fragmentation. , 2005, Genes & development.

[87]  Sophia Adamia,et al.  Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma. , 2005, Blood.

[88]  Steffen Hauptmann,et al.  Significance of HDMX‐S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis , 2005, International journal of cancer.

[89]  P. Hainaut,et al.  WITHDRAWN: Expression of p53, p63, and p73 isoforms in squamous cell carcinoma and adenocarcinoma of esophagus☆,☆☆ , 2005, Biochemical and Biophysical Research Communications - BBRC.

[90]  K. Konstantopoulos,et al.  CD44 on LS174T colon carcinoma cells possesses E-selectin ligand activity. , 2005, Cancer research.

[91]  F. Végran,et al.  Distinct expression of Survivin splice variants in breast carcinomas. , 2005, International journal of oncology.

[92]  Y. Xu,et al.  The effect of isoforms of the cell polarity protein, human ASIP, on the cell cycle and Fas/FasL-mediated apoptosis in human hepatoma cells , 2005, Cellular and Molecular Life Sciences CMLS.

[93]  J. Rowley,et al.  Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[94]  D. Albertson,et al.  Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability , 2005, Nature.

[95]  Tyson A. Clark,et al.  Nova regulates brain-specific splicing to shape the synapse , 2005, Nature Genetics.

[96]  J. Riedinger,et al.  Implication des transcrits alternatifs de la caspase 3 et de la survivine dans la chimiorésistance , 2005 .

[97]  Phillip A. Sharp,et al.  Regulation of CD44 Alternative Splicing by SRm160 and Its Potential Role in Tumor Cell Invasion , 2006, Molecular and Cellular Biology.